<DOC>
	<DOCNO>NCT01335477</DOCNO>
	<brief_summary>Idiopathic Pulmonary Fibrosis ( IPF ) chronic disease unknown cause result scar lung high unmet medical need effective treatment halt lung function decline , delay avoid exacerbation ( flare-ups ) , ultimately reduce death rate . In large Phase 2 trial ( 1199.30 ) ( NCT00514683 ) , investigate effect 52 week treatment BIBF 1120 patient IPF , positive effect see lung function patient treat high dose BIBF 1120 compare placebo . Hence purpose trial investigate confirm efficacy safety BIBF 1120 high dose treat patient IPF , compare placebo . The trial conduct prospective , randomised design aim collect safety efficacy data . Respiratory function globally accept assessment treatment effect IPF patient . The chosen endpoint ( Forced Vital Capacity ( FVC ) decline ) easy obtain part usual examination do IPF patient .</brief_summary>
	<brief_title>Safety Efficacy BIBF 1120 High Dose Idiopathic Pulmonary Fibrosis Patients II</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Age &gt; = 40 year ; 2 . IPF diagnose , accord recent American Thoracic Society ( ATS ) , European Respiratory Society ( ERS ) , Japanese Respiratory Society ( JRS ) , Latin American Thoracic Association ( ALAT ) IPF guideline diagnosis management , within 5 year ; 3 . Combination High Resolution Computerized Tomography ( HRCT ) pattern , available surgical lung biopsy pattern , assessed central reviewer , consistent diagnosis IPF 4 . Dlco ( correct Hb ) : 30 % 79 % predict normal ; 5.FVC &gt; = 50 % predict normal Exclusion criterion : 1 . Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) &gt; 1.5 x Upper Limit Normal ( ULN ) 2 . Bilirubin &gt; 1.5 x ULN ; 3 . Relevant airways obstruction ( i.e . prebronchodilator FEV1/FVC &lt; 0.7 ) ; 4 . Patient likely lung transplantation study ( transplantation list acceptable participation ) ; 5 . Myocardial infarction within 6 month ; 6 . Unstable angina within 1 month ; 7 . Bleeding risk ( genetic predisposition ; fibrinolysis fulldose therapeutic anticoagulation high dose antiplatelet therapy ; history hemorrhagic CNS event within 12 month ; haemoptysis haematuria active gastrointestinal bleeding ulcer major injury surgery within 3 month ) ; 8 . Thrombotic risk ( inherited predisposition ; history thrombotic event ( include stroke transient ischemic attack ) within 12 month ; 9. International normalise ratio ( INR ) &gt; 2 , prolongation prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 50 % institutional ULN ) ; 10 . NACetyl Cystein , prednisone &gt; 15mg/day equivalent receive within 2 week visit 1 ; 11 . Pirfenidone , azathioprine , cyclophosphamide , cyclosporine A receive within 8 week visit 1 ;</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>